Epiminder Ltd (ASX: EPI) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Epiminder Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$50.80 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
216.67 million
Earnings per share
-0.283
Dividend per share
N/A
Year To Date Return
-71.57%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Epiminder Ltd (ASX: EPI)
Latest News
Broker Notes
Morgans tips a 600%+ return for this ASX biotech stock
Healthcare Shares
Two ASX healthcare shares that could triple in the next year
Small Cap Shares
Morgans names 3 small-cap ASX shares to buy
Small Cap Shares
Guess which small cap ASX stock is rising on 'watershed moment' in the US
Speculative
These speculative ASX stocks could rise 90% to 140%
EPI ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Epiminder Ltd
Epiminder Ltd. develops the Minder® system, a technology currently under evaluation that aims to improve epilepsy treatment by continuously recording brain activity data to reveal previously unseen epileptic episodes. The company is based in East Melbourne, Australia. The system is designed to provide clinicians with crucial data to enhance treatment decisions and empower patients through real-time information sharing and collaboration. The Australian company was founded by Mark Cook. Rohan J. Hoare has been the CEO of the company since 2020.
EPI Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 25 Sep 2026 | $0.29 | $0.01 | 3.57% | 71,287 | $0.29 | $0.29 | $0.29 |
| 24 Sep 2026 | $0.28 | $0.02 | 7.55% | 213,975 | $0.27 | $0.29 | $0.27 |
| 23 Sep 2026 | $0.27 | $0.02 | 8.00% | 140,821 | $0.27 | $0.27 | $0.25 |
| 22 Sep 2026 | $0.25 | $-0.03 | -10.71% | 569,151 | $0.28 | $0.28 | $0.25 |
| 21 Sep 2026 | $0.28 | $-0.01 | -3.45% | 127,763 | $0.29 | $0.29 | $0.28 |
| 18 Sep 2026 | $0.29 | $0.00 | 0.00% | 26,705 | $0.30 | $0.30 | $0.29 |
| 17 Sep 2026 | $0.29 | $0.01 | 3.51% | 186,896 | $0.29 | $0.30 | $0.29 |
| 16 Sep 2026 | $0.29 | $0.00 | 0.00% | 40,526 | $0.29 | $0.29 | $0.29 |
| 15 Sep 2026 | $0.28 | $-0.02 | -6.67% | 130,417 | $0.30 | $0.30 | $0.28 |
| 14 Sep 2026 | $0.30 | $0.00 | 0.00% | 65,633 | $0.31 | $0.31 | $0.30 |
| 11 Sep 2026 | $0.30 | $-0.01 | -3.28% | 48,365 | $0.31 | $0.31 | $0.30 |
| 10 Sep 2026 | $0.31 | $-0.01 | -3.23% | 42,512 | $0.32 | $0.32 | $0.30 |
| 09 Sep 2026 | $0.31 | $-0.01 | -3.17% | 138,246 | $0.31 | $0.36 | $0.31 |
| 08 Sep 2026 | $0.32 | $0.00 | 0.00% | 59,389 | $0.32 | $0.32 | $0.32 |
| 07 Sep 2026 | $0.31 | $-0.01 | -3.13% | 129,948 | $0.33 | $0.33 | $0.31 |
| 04 Sep 2026 | $0.32 | $0.00 | 0.00% | 243,708 | $0.33 | $0.33 | $0.32 |
| 03 Sep 2026 | $0.32 | $-0.01 | -3.08% | 121,598 | $0.33 | $0.34 | $0.32 |
| 02 Sep 2026 | $0.33 | $-0.02 | -5.71% | 222,496 | $0.35 | $0.35 | $0.30 |
| 01 Sep 2026 | $0.35 | $0.01 | 2.94% | 116,815 | $0.36 | $0.36 | $0.34 |
| 31 Aug 2026 | $0.34 | $-0.01 | -2.86% | 20,138 | $0.36 | $0.36 | $0.34 |
| 28 Aug 2026 | $0.35 | $-0.02 | -5.48% | 35,424 | $0.37 | $0.37 | $0.35 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Sep 2026 | Donal O'Dwyer | Buy | 50,000 | $16,500 |
On-market trade.
|
| 01 Sep 2026 | Donal O'Dwyer | Buy | 50,000 | $17,550 |
On-market trade.
|
| 01 Sep 2026 | Philip Binns | Buy | 14,000 | $4,830 |
On-market trade.
|
| 18 Aug 2026 | Jeffrey Sells | Buy | 25,000 | $9,875 |
On-market trade.
|
| 17 Aug 2026 | Donal O'Dwyer | Buy | 60,000 | $22,797 |
On-market trade.
|
| 11 Aug 2026 | Donal O'Dwyer | Buy | 75,000 | $23,719 |
On-market trade.
|
| 10 Aug 2026 | Robert Klupacs | Buy | 15,000 | $4,725 |
On-market trade.
|
| 02 Jun 2026 | Philip Binns | Buy | 11,235 | $4,943 |
On-market trade.
|
| 15 May 2026 | Robert Klupacs | Buy | 10,000 | $4,690 |
On-market trade.
|
| 15 May 2026 | Jeffrey Sells | Buy | 45,475 | $20,691 |
On-market trade.
|
| 14 May 2026 | Donal O'Dwyer | Buy | 21,500 | $9,890 |
On-market trade.
|
| 14 May 2026 | Patricia ORourke | Buy | 11,350 | $5,107 |
On-market trade.
|
| 16 Mar 2026 | Philip Binns | Buy | 7,352 | $4,668 |
On-market trade.
|
| 27 Feb 2026 | Robert Klupacs | Buy | 7,500 | $6,375 |
On-market trade.
|
| 08 Dec 2025 | Patricia ORourke | Buy | 10,000 | $11,074 |
On-market trade. As per announcement on 15/12/2025
|
| 08 Dec 2025 | Jeffrey Sells | Buy | 22,525 | $24,252 |
On-market trade.
|
| 08 Dec 2025 | Donal O'Dwyer | Buy | 33,334 | $35,893 |
On-market trade.
|
| 05 Dec 2025 | Robert Klupacs | Buy | 10,000 | $10,049 |
On-market trade.
|
| 04 Dec 2025 | Robert Klupacs | Buy | 10,000 | $10,789 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Jeffrey Sells | Non-Executive Director | May 2025 |
Mr Sells worked in chief financial officer roles and led business units for over 25 years. He also worked at Sigma Healthcare Limited for 12 years finishing as the Chief Commercial Officer responsible for a wholesale and retail business and prior to that he was Chief Financial Officer. He is the chairperson of the Audit Committee.
|
| Mr Donal Paul O'Dwyer | Non-Executive Director | Apr 2025 |
Mr O'Dwyer has a knowledge of the health industry globally, after more than 40 years in senior executive and non-executive director roles within the healthcare products and medical device sectors. He is a member of the Risk Committee.
|
| Mr Robert John Klupacs | Non-Executive Director | Sep 2017 |
Mr Klupacs has a career to date within both private and publicly traded companies as well as the academic arena. He is also the founder of 28 startup companies and with over 30 years of corporate experience, is experienced in translating and commercializing intellectual property into commercial products or investable corporate vehicles.
|
| Ms Patricia ORourke | Non-Executive Director |
Ms Orourke has more than 35 years of experience in the health and research industry, including both the public and private sectors. She has held multiple board, chief executive and executive leadership positions during this time. She is currently a non-executive director of Australian Unity, a national social enterprise in health, wealth and care with over 370,000 members, 750,000 customers and employs 10,000 people across the country. She is a member of the Risk Committee.
|
|
| Mr Philip Binns | Non-Executive ChairmanNon-Executive Director | Jun 2018 |
Mr Binns has over 30 years of experience leading organisations across the scientific and life science industries. In 2008, he was appointed by the Federal Government to chair the Future Manufacturing Innovation Council and in 2012 served on the Prime Minister's Manufacturing Task Force.
|
| Dr Rohan Hoare | Chief Executive OfficerManaging Director | Dec 2022 |
Dr Hoare has experience in medical devices both in large established med tech companies and start ups. He is a director of Brainmatterz and Xnerve. In addition, Rohan is on the board of the Epilepsy Foundation of Texas.
|
| Ms Belinda Ann Cleminson | Joint Company Secretary | Dec 2025 |
-
|
| Mr Mark McLellan | Chief Financial OfficerJoint Company Secretary | Dec 2025 |
-
|
| Mark McLellan | Chief Financial OfficerJoint Company Secretary |
-
|
|
| John Heasman | COO |
-
|
|
| Belinda Ann Cleminson | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Cochlear Investments Pty Ltd | 77,982,069 | 35.99% |
| Hsbc Custody Nominees (Australia) Limited | 18,782,011 | 8.67% |
| The Bionics Institute Of Australia | 15,773,644 | 7.28% |
| J P Morgan Nominees Australia Pty Limited | 11,685,194 | 5.39% |
| St Vincents Hospital (Melbourne) | 7,821,432 | 3.61% |
| Umc Commercialisation Pty Ltd | 7,543,140 | 3.48% |
| Bnp Paribas Noms Pty Ltd | 7,487,432 | 3.46% |
| Argo Investments Limited | 5,999,999 | 2.77% |
| Ubs Nominees Pty Ltd | 3,986,925 | 1.84% |
| Citicorp Nominees Pty Limited | 3,775,270 | 1.74% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 3,623,528 | 1.67% |
| Mr Michael Andrew Murphy & Mrs Michelle Maree Murphy <Murphy Family Super A/C> | 2,256,572 | 1.04% |
| Mirrabooka Investments Limited | 2,161,292 | 1.00% |
| First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> | 1,890,311 | 0.87% |
| The Nigel Ashton Family Pty Ltd | 1,695,362 | 0.78% |
| Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,512,853 | 0.70% |
| Rubino Group Pty Ltd <Rubino Group A/C> | 1,330,000 | 0.61% |
| Anne Shireen Cook <Cook Family Investment A/C> | 1,244,465 | 0.57% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 1,093,795 | 0.51% |
| Netwealth Investments Limited <Wrap Services A/C> | 947,461 | 0.44% |
